Study shows MD Anderson-developed drug effective in overcoming ibrutinib resistance in mantle cell lymphoma

Study shows MD Anderson-developed drug effective in overcoming ibrutinib resistance in mantle cell lymphoma

Michael Wang, M.D.

  VIDEO: Pre-clinical study shows MD Anderson-developed drug effective for mantle cell lymphoma treatment. A study at The University of Texas MD Anderson Cancer Center demonstrated how a small molecule drug discovered at the institution may help overcome resistance to treatment with ibrutinib in patients with mantle cell lymphoma. The drug, IACS-10759, was the first therapy to be developed from concept to clinical trial by MD Anderson’s Therapeutics Discovery division, a unique drug-discovery engine created to answer unmet patient needs. IACS-10759 is […]